文献速递细菌感染、耐药与抗菌药物

BLOOMY预测评分用于住院成人血流感染14天和6个月死亡率的开发与验证:一项多中心、前瞻性队列研究

Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study.
PubMed 文献 · Lancet Infect Dis · 2022-01-19

BLOOMY多中心前瞻性队列研究在6家德国三级大学医院开发并验证了预测血流感染患者14天和6个月死亡率的两套评分。推导队列纳入2568例,14天死亡率模型C统计量为0.873,6个月为0.807;验证队列1023例,两评分显示良好区分度和预测值。

要点

  • BLOOMY 14天评分验证队列敏感度61.32%、特异度86.36%、阳性预测值37.57%、阴性预测值94.35%。
  • BLOOMY 6个月评分验证队列敏感度69.93%、特异度66.44%、阳性预测值40.82%、阴性预测值86.97%。
  • 评分预测因子包括年龄、体重指数、血小板和白细胞计数、C反应蛋白、恶性肿瘤、院内获得和病原体等。

核心结论

  • BLOOMY评分显示出良好的区分度和预测值,可支持制定血流感染管理方案,并帮助估计血流感染的短期和长期负担。

研究设计与样本

  • BLOOMY研究是一项在6家德国三级大学医院开展的前瞻性、多中心队列研究,用于开发和验证评估血流感染患者14天和6个月死亡率的两套评分。
  • 排除年龄小于18岁或入住眼科或精神科病房的患者;前瞻性收集第0天、第3天以及从第7天起每周的微生物学、临床、实验室、治疗和生存数据,随访6个月。
  • 推导队列纳入2017年2月1日至2019年1月31日期间招募的4179例合格患者中的2568例(61.5%),分析纳入第3天仍存活的所有患者;验证队列纳入2019年10月9日至2020年12月31日期间招募的1023例血流感染患者。
  • 预测评分采用逻辑回归和Cox比例风险模型结合机器学习方法开发,验证使用C统计量,预测准确性通过敏感度、特异度和预测值评估。

主要发现

  • 推导队列院内死亡率为23.75%(95% CI 22.15-25.44;2568例中610例),6个月死亡率为41.55%(39.54-43.59;2284例中949例)。
  • 14天死亡率模型C统计量为0.873(95% CI 0.849-0.896),6个月死亡率模型C统计量为0.807(0.784-0.831)。
  • 14天和6个月死亡率的模型预测因子均包括年龄、体重指数、血小板和白细胞计数、C反应蛋白浓度、恶性肿瘤(即合并症)、院内获得和病原体。
  • 14天死亡率额外预测因子包括第3天精神状态、低血压和需要机械通气;6个月死亡率额外预测因子包括感染灶、院内并发症和治疗结束时肾小球滤过率。
  • BLOOMY 14天评分验证队列敏感度61.32%(95% CI 51.81-70.04)、特异度86.36%(83.80-88.58)、阳性预测值37.57%(30.70-44.99)、阴性预测值94.35%(92.42-95.80)。

临床怎么用

  • 原文结论指出BLOOMY评分显示出良好的区分度和预测值,可支持制定血流感染管理方案,并帮助估计血流感染的短期和长期负担。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The burden of bloodstream infections remains high worldwide and cannot be confined to short-term in-hospital mortality. We aimed to develop scores to predict short-term and long-term mortality in patients with bloodstream infections. METHODS: The Bloodstream Infection due to Multidrug-resistant Organisms: Multicenter Study on Risk Factors and Clinical Outcomes (BLOOMY) study is a prospective, multicentre cohort study at six German tertiary care university hospitals to develop and validate two scores assessing 14-day and 6-month mortality in patients with bloodstream infections. We excluded patients younger than 18 years or who were admitted to an ophthalmology or psychiatry ward. Microbiological, clinical, laboratory, treatment, and survival data were prospectively collected on day 0 and day 3 and then from day 7 onwards, weekly. Participants were followed up for 6 months. All patients in the derivation cohort who were alive on day 3 were included in the analysis. Predictive scores were developed using logistic regression and Cox proportional hazards models with a machine-learning approach. Validation was completed using the C statistic and predictive accuracy was assessed using sensitivity, specificity, and predictive values. FINDINGS: Between Feb 1, 2017, and Jan 31, 2019, 2568 (61·5%) of 4179 eligible patients were recruited into the derivation cohort. The in-hospital mortality rate was 23·75% (95% CI 22·15-25·44; 610 of 2568 patients) and the 6-month mortality rate was 41·55% (39·54-43·59; 949 of 2284). The model predictors for 14-day mortality (C statistic 0·873, 95% CI 0·849-0·896) and 6-month mortality (0·807, 0·784-0·831) included age, body-mass index, platelet and leukocyte counts, C-reactive protein concentrations, malignancy (ie, comorbidity), in-hospital acquisition, and pathogen. Additional predictors were, for 14-day mortality, mental status, hypotension, and the need for mechanical ventilation on day 3 and, for 6-month mortality, focus of infection, in-hospital complications, and glomerular filtration rate at the end of treatment. The scores were validated in a cohort of 1023 patients with bloodstream infections, recruited between Oct 9, 2019, and Dec 31, 2020. The BLOOMY 14-day score showed a sensitivity of 61·32% (95% CI 51·81-70·04), a specificity of 86·36% (83·80-88·58), a positive predictive value (PPV) of 37·57% (30·70-44·99), and a negative predictive value (NPV) of 94·35% (92·42-95·80). The BLOOMY 6-month score showed a sensitivity of 69·93% (61·97-76·84), a specificity of 66·44% (61·86-70·73), a PPV of 40·82% (34·85-47·07), and a NPV of 86·97% (82·91-90·18). INTERPRETATION: The BLOOMY scores showed good discrimination and predictive values and could support the development of protocols to manage bloodstream infections and also help to estimate the short-term and long-term burdens of bloodstream infections. FUNDING: DZIF German Center for Infection Research. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Tacconelli E, Göpel S, Gladstone BP, et al. Development and validation of BLOOMY prediction scores for 14-day and 6-month mortality in hospitalised adults with bloodstream infections: a multicentre, prospective, cohort study. Lancet Infect Dis. 2022. PMID: 35065060. doi:10.1016/S1473-3099(21)00587-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。